Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects
The DOI matches its Crossref record.
Abstract
The regulation of glutathione and various glutathione-dependent enzymes has been studied in two ovarian adenocarcinoma cell lines derived from a patient before (PE01) and after (PE04) the onset of drug resistance to cis-platinum, chlorambucil and 5-fluorouracil. Reduced glutathione levels were higher in the drug resistant cells (PE04). This could possibly be attributed to a much higher (6.5-fold) gamma-glutamyl-transpeptidase activity. In addition, glutathione-S-transferase (GST) and glutathione peroxidase were 2.9- and 2.3-fold higher in this cell line. Analysis of the GST subunit composition showed both cell lines contained high levels of the acidic GST and lower concentrations of a basic isozyme. The difference in GST activity between PE01 and PE04 did not appear to be related to the levels of these GST subunits. GSH, glutathione peroxidase and gamma-glutamylcysteinyl synthetase were all found to be regulated during the cell cycle, higher levels being detected in logarithmic versus confluent cultures of PE01 and PE04 and MCF7. This did affect some of the differences between PE01 and PE04 and therefore may be a contributing factor to the differential sensitivity of these cells to cytotoxic compounds. The above data provide the first evidence that tumour cells obtained from a patient before and after the onset of drug resistance have significant differences in glutathione-dependent enzyme content.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Hayes, J. D., & Pulford, D. J. (1995) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239509083491 · Cited by 3,464
Self-citationMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Role of Glutathione in Cancer Progression and Chemoresistance
Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208
“In addition, it has been demonstrated that GGT-overexpressing cells were more resistant to hydrogen peroxide [67] and chemotherapics, such as doxorubicin [68], cisplatin [64], and 5-fluorouracil [69].”
BackgroundGlutathione-Associated Enzymes In Anticancer Drug Resistance
Tew, K. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3143 · Cited by 856
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
The interaction between ferroptosis and lipid metabolism in cancer
Li, D., & Li, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00216-5 · Cited by 703
Glutathione Transferases and Cancer
Tsuchida, S., & Sato, K. (1992) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239209082566 · Cited by 537
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D'Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 536
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S.-H., & Chang, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 428
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors
Rampling, R., Cruickshank, G., Lewis, A. D., Fitzsimmons, S. A., & Workman, P. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90432-4 · Cited by 304
Self-citationSingh, R. K., Kumar, S., Prasad, D. N., & Bhardwaj, T. R. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.001 · Cited by 282
Expression of γ-glutamyltransferase in cancer cells and its significance in drug resistance
Pompella, A., De Tata, V., Paolicchi, A., & Zunino, F. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.005 · Cited by 280
Hanigan, M. H., & Ricketts, W. A. (1993) · Biochemistry · doi:10.1021/bi00075a026 · Cited by 272
(2014) · Advances in Cancer Research · doi:10.1016/b978-0-12-420117-0.00003-7 · Cited by 271
Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
Ling, X., Tu, J., Wang, J., Shajii, A., Kong, N., Feng, C., Zhang, Y., Yu, M., Xie, T., Bharwani, Z., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06400 · Cited by 263
Mistry, P., Kelland, L., Abel, G., Sidhar, S., & Harrap, K. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.279 · Cited by 261
The Enzymes of Glutathione Synthesis: γ‐Glutamylcysteine Synthetase
Griffith, O. W., & Mulcahy, R. T. (1999) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123195.ch7 · Cited by 253
In Vivo Brain GSH: MRS Methods and Clinical Applications
Bottino, F., Lucignani, M., Napolitano, A., Dellepiane, F., Visconti, E., Rossi Espagnet, M. C., & Pasquini, L. (2021) · Antioxidants · doi:10.3390/antiox10091407 · Cited by 50
“For example, a direct correlation between glutathione-S-transferases (GST) expression and anti-cancer drug resistance has been demonstrated [105,106], including through bioptic evidence from tumor tissues that gained drug therapy resistance [107,108].”
Background
Metadata
- Authors
- Lewis, A. D., Hayes, J. D., & Wolf, C. R.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 1988
- Volume
- 9
- Issue
- 7
- Pages
- 1283-1287
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2013478379
- Cited by
- 223
- References
- 0
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.